tDCS delivers a low-level, constant electrical current (typically 1–2mA) through electrodes placed on the scalp. Unlike rTMS, it does not directly induce neuronal firing — instead, it modulates the resting membrane potential of neurons, making them either more or less likely to fire.
At BrainAid Clinics, tDCS is offered as an investigational treatment under full psychiatrist oversight. It is not TGA-approved for any indication in Australia and is used off-label with full informed consent.
One significant advantage of tDCS is its portability. Home-based treatment protocols are available, allowing patients to use a clinician-programmed device at home with ongoing clinical monitoring.
Important: tDCS is not TGA-approved for any indication in Australia. It is offered as an investigational modality under psychiatrist oversight and full informed consent. It should not be considered a replacement for TGA-approved treatments.